导致高效HIV-1蛋白酶抑制剂的哌嗪磺酰胺核心结构的设计与合成
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.
作者信息
Bungard Christopher J, Williams Peter D, Schulz Jurgen, Wiscount Catherine M, Holloway M Katharine, Loughran H Marie, Manikowski Jesse J, Su Hua-Poo, Bennett David J, Chang Lehua, Chu Xin-Jie, Crespo Alejandro, Dwyer Michael P, Keertikar Kartik, Morriello Gregori J, Stamford Andrew W, Waddell Sherman T, Zhong Bin, Hu Bin, Ji Tao, Diamond Tracy L, Bahnck-Teets Carolyn, Carroll Steven S, Fay John F, Min Xu, Morris William, Ballard Jeanine E, Miller Michael D, McCauley John A
机构信息
Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, United States.
Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.
出版信息
ACS Med Chem Lett. 2017 Nov 13;8(12):1292-1297. doi: 10.1021/acsmedchemlett.7b00386. eCollection 2017 Dec 14.
Abstract
Using the HIV-1 protease binding mode of and as inspiration, a novel aspartate binding bicyclic piperazine sulfonamide core was designed and synthesized. The resulting HIV-1 protease inhibitor containing this core showed an 60-fold increase in enzyme binding affinity and a 10-fold increase in antiviral activity relative to .
摘要
以[具体药物1]和[具体药物2]的HIV-1蛋白酶结合模式为灵感，设计并合成了一种新型的含天冬氨酸结合的双环哌嗪磺酰胺核心结构。相对于[对比药物]，含有该核心结构的HIV-1蛋白酶抑制剂的酶结合亲和力提高了60倍，抗病毒活性提高了10倍。
相似文献
1
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.导致高效HIV-1蛋白酶抑制剂的哌嗪磺酰胺核心结构的设计与合成
ACS Med Chem Lett. 2017 Nov 13;8(12):1292-1297. doi: 10.1021/acsmedchemlett.7b00386. eCollection 2017 Dec 14.
2
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.MK-8718的发现，一种含有新型吗啉天冬氨酸结合基团的HIV蛋白酶抑制剂。
ACS Med Chem Lett. 2016 May 9;7(7):702-7. doi: 10.1021/acsmedchemlett.6b00135. eCollection 2016 Jul 14.
3
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.以内消旋双环脲作为P2配体的强效HIV-1蛋白酶抑制剂：基于结构的设计、合成、生物学评价及蛋白质-配体X射线研究
Org Biomol Chem. 2008 Oct 21;6(20):3703-13. doi: 10.1039/b809178a. Epub 2008 Aug 11.
4
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.新型HIV蛋白酶抑制剂的基于结构的设计：含磺酰胺的4-羟基香豆素和4-羟基-2-吡喃酮作为有效的非肽类抑制剂
J Med Chem. 1996 Jun 7;39(12):2400-10. doi: 10.1021/jm950888f.
5
Approaches to the design of HIV protease inhibitors with improved resistance profiles.设计具有改善耐药性的HIV蛋白酶抑制剂的方法。
Curr Opin HIV AIDS. 2008 Nov;3(6):633-41. doi: 10.1097/COH.0b013e328313911d.
6
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.发现具有皮摩尔亲和力的HIV-1蛋白酶抑制剂，其包含N-芳基-恶唑烷酮-5-甲酰胺作为新型P2配体。
J Med Chem. 2006 Dec 14;49(25):7342-56. doi: 10.1021/jm060666p.
7
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.靶向蛋白质主链的HIV蛋白酶抑制剂设计：一种对抗耐药性的有效策略。
Acc Chem Res. 2008 Jan;41(1):78-86. doi: 10.1021/ar7001232. Epub 2007 Aug 28.
8
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.一种新型含双四氢呋喃基聚氨酯的非肽类蛋白酶抑制剂（PI）GRL-98065，在体外对多种耐PI的人类免疫缺陷病毒具有强效作用。
Antimicrob Agents Chemother. 2007 Jun;51(6):2143-55. doi: 10.1128/AAC.01413-06. Epub 2007 Mar 19.
9
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.基于结构的设计：一系列新型环酰胺衍生的HIV-1蛋白酶抑制剂的合成与生物学评价
J Med Chem. 2005 May 19;48(10):3576-85. doi: 10.1021/jm050019i.
10
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.一系列含有羟乙基仲胺过渡态类似物的高效HIV-1蛋白酶抑制剂：合成、酶抑制及抗病毒活性
J Med Chem. 1992 Jul 10;35(14):2525-33. doi: 10.1021/jm00092a002.
引用本文的文献
1
Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV Protease.理解耐药性HIV蛋白酶的结构、动力学及作用机制。
ACS Omega. 2023 Mar 7;8(11):9748-9763. doi: 10.1021/acsomega.2c08279. eCollection 2023 Mar 21.
2
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance.超越达芦那韦：新一代 HIV-1 蛋白酶抑制剂抵抗耐药性的最新进展。
Chem Commun (Camb). 2022 Oct 20;58(84):11762-11782. doi: 10.1039/d2cc04541a.
3
Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands.设计、合成及含 C-4 取代的三环六氢呋喃衍生物作为 P2 配体的强效 HIV-1 蛋白酶抑制剂的 X 射线晶体结构研究。
ChemMedChem. 2022 May 4;17(9):e202200058. doi: 10.1002/cmdc.202200058. Epub 2022 Mar 4.
4
Synthesis, study (DFT, ADMET) and crystal structure of novel sulfamoyloxy-oxazolidinones: Interaction with SARS-CoV-2.新型氨磺酰氧基恶唑烷酮的合成、研究（密度泛函理论、药物代谢和毒性预测）及晶体结构：与严重急性呼吸综合征冠状病毒2的相互作用
J Mol Struct. 2022 Jun 5;1257:132579. doi: 10.1016/j.molstruc.2022.132579. Epub 2022 Feb 5.
5
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.直接作用抗病毒药物及其他药物的耐药性规避药物设计策略。
Chem Rev. 2021 Mar 24;121(6):3238-3270. doi: 10.1021/acs.chemrev.0c00648. Epub 2021 Jan 7.
6
Design, Synthesis, Antiviral Bioactivity, and Mechanism of the Ferulic Acid Ester-Containing Sulfonamide Moiety.含阿魏酸酯磺酰胺部分的设计、合成、抗病毒生物活性及作用机制
ACS Omega. 2020 Jul 29;5(31):19721-19726. doi: 10.1021/acsomega.0c02421. eCollection 2020 Aug 11.
7
Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.哌啶骨架作为新型含环丙基 HIV-1 蛋白酶抑制剂的 P2 配体：基于结构的设计、合成、生物评价及对接研究。
PLoS One. 2020 Jul 22;15(7):e0235483. doi: 10.1371/journal.pone.0235483. eCollection 2020.
8
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.含双四氢呋喃的拟对称二肽等排体的强效杂交型HIV-1蛋白酶抑制剂的结构分析
J Med Chem. 2020 Aug 13;63(15):8296-8313. doi: 10.1021/acs.jmedchem.0c00529. Epub 2020 Aug 3.
9
Inhibition of HIV-1 Protease by (L.).（拉汉属名未明确，无法准确翻译属名部分）对HIV-1蛋白酶的抑制作用 。
Evid Based Complement Alternat Med. 2020 Jun 7;2020:9648056. doi: 10.1155/2020/9648056. eCollection 2020.
10
Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.基于结构的新型三环 P2 配体高活性 HIV-1 蛋白酶抑制剂的设计：设计、合成、生物学和 X 射线结构研究。
J Med Chem. 2020 May 14;63(9):4867-4879. doi: 10.1021/acs.jmedchem.0c00202. Epub 2020 Apr 29.
本文引用的文献
1
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.MK-8718的发现，一种含有新型吗啉天冬氨酸结合基团的HIV蛋白酶抑制剂。
ACS Med Chem Lett. 2016 May 9;7(7):702-7. doi: 10.1021/acsmedchemlett.6b00135. eCollection 2016 Jul 14.
2
Investigational protease inhibitors as antiretroviral therapies.作为抗逆转录病毒疗法的研究性蛋白酶抑制剂。
Expert Opin Investig Drugs. 2016 Oct;25(10):1189-200. doi: 10.1080/13543784.2016.1212837. Epub 2016 Aug 2.
3
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.用于治疗艾滋病毒/艾滋病的HIV-1蛋白酶抑制剂开发的最新进展
J Med Chem. 2016 Jun 9;59(11):5172-208. doi: 10.1021/acs.jmedchem.5b01697. Epub 2016 Jan 22.
4
Regioselective ring-opening of amino acid-derived chiral aziridines: an easy access to cis-2,5-disubstituted chiral piperazines.氨基酸衍生的手性氮丙啶的区域选择性开环：顺式-2,5-二取代手性哌嗪的易得途径。
Chem Asian J. 2011 Jan 3;6(1):189-97. doi: 10.1002/asia.201000554.
5
Expedite protocol for construction of chiral regioselectively N-protected monosubstituted piperazine, 1,4-diazepane, and 1,4-diazocane building blocks.构建手性区域选择性N-保护的单取代哌嗪、1,4-二氮杂环庚烷和1,4-二氮杂环辛烷结构单元的快速方案。
J Org Chem. 2009 Aug 7;74(15):5652-5. doi: 10.1021/jo900441s.
6
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.PL-100，一种对耐药性具有高遗传屏障的新型HIV-1蛋白酶抑制剂：一项体外筛选研究。
J Med Virol. 2008 Dec;80(12):2053-63. doi: 10.1002/jmv.21329.
7
Active human immunodeficiency virus protease is required for viral infectivity.活跃的人类免疫缺陷病毒蛋白酶是病毒感染性所必需的。
Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90. doi: 10.1073/pnas.85.13.4686.
8
Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.体外合成的HIV-1 gag多聚蛋白的切割：病毒蛋白酶的顺序切割
AIDS Res Hum Retroviruses. 1989 Dec;5(6):577-91. doi: 10.1089/aid.1989.5.577.
9
Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor.与基于羟乙烯的抑制剂复合的化学合成人免疫缺陷病毒1型蛋白酶的2.5埃分辨率结构。
Biochemistry. 1991 Feb 12;30(6):1600-9. doi: 10.1021/bi00220a023.
Zotero 插件